Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment Options in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer Patients

NCT01782651 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01782651
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01782651 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment Options in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer Patients
Lead sponsor
GlaxoSmithKline
Phase
Observational
Overall status
Completed
Start date
August 31, 2014
Completion date
July 31, 2015
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms, breast